Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

1.150 +0.030 (+2.68%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,289
Open 1.130
Bid (Size) 1.080 (1)
Ask (Size) 1.280 (1)
Prev. Close 1.120
Today's Range 1.120 - 1.150
52wk Range 0.8924 - 2.124
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
From Rafael Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-30.72%
-30.72%
1 Month
-1.71%
-1.71%
3 Month
-10.85%
-10.85%
6 Month
-37.84%
-37.84%
1 Year
-21.23%
-21.23%

More News

Read More
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023
Via InvestorPlace
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Bridgeline Digital Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
From Cyclo Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.